Nektar Therapeutics beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging +10.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-2.06 | $-1.23 | +40.3% | Beat | Q2 FY26 call |
| Q1 FY26 | $-1.74 | $-1.82 | -4.6% | Miss | |
| Q4 FY25 | $-2.76 | $-1.78 | +35.5% | Beat | |
| Q3 FY25 | $-2.85 | $-1.85 | +35.1% | Beat | |
| Q2 FY25 | $-3.13 | $-2.95 | +5.8% | Beat | |
| Q1 FY25 | $-0.18 | $-0.22 | -22.2% | Miss | |
| Q4 FY24 | $-0.13 | $-0.15 | -15.4% | Miss | |
| Q3 FY24 | $-0.23 | $-0.18 | +21.7% | Beat | |
| Q2 FY24 | $-0.21 | $-0.25 | -19.1% | Miss | |
| Q1 FY24 | $-0.21 | $-0.18 | +14.3% | Beat | |
| Q4 FY23 | $-0.20 | $-0.22 | -10.0% | Miss | |
| Q3 FY23 | $-0.18 | $-0.19 | -5.6% | Miss |
Back to NKTR overview · NKTR holders · NKTR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.